Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody
Amgen has shed light on its phase 2 lupus win, revealing that its monoclonal antibody daxdilimab was tied to a 6-point reduction in disease severity at the lower dose. Click here to view original post […]
